Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
21.8M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
8.92M
-
Shares change
-
+229K
-
Total reported value, excl. options
-
$121M
-
Value change
-
+$8.91M
-
Number of buys
-
29
-
Number of sells
-
-12
-
Price
-
$13.52
Significant Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 (AARD) as of Q2 2025
44 filings reported holding AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 as of Q2 2025.
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 (AARD) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.92M shares
of 21.8M outstanding shares and own 40.94% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (3.92M shares), CITADEL ADVISORS LLC (1.28M shares), Laurion Capital Management LP (989K shares), Cormorant Asset Management, LP (800K shares), VANGUARD GROUP INC (461K shares), SILVERARC CAPITAL MANAGEMENT, LLC (287K shares), Schonfeld Strategic Advisors LLC (279K shares), BlackRock, Inc. (206K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (175K shares), and GEODE CAPITAL MANAGEMENT, LLC (137K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.